EGFR and neoplasm: In addition to the tumor stage, it is crucial to consider the age of the patients, as the probability of KRAS mutation increases with age.20 KRAS mutations lead to the activation of downstream signaling pathways such as the MAPK/ERK and PI3K/AKT pathways, while LEDGF/p75 can enhance the transcriptional activation of genes within these pathways, thereby promoting tumorigenesis and enhancing the growth and survival of KRAS-mutant EGFR inhibitor-resistant cancer cells.